Paper Review Records
全部论文审稿周期
16 篇有效样本 · 按发表日期由新到旧排列
审稿天数=录用日期-收稿日期；保留 PDF/DOI/网页源链接
221
天
IDH1 -mutant vaccine in newly diagnosed astrocytoma: final analysis of the multicenter, single-arm, open-label, first-in-human phase 1 NOA16 trial
作者
Lukas Bunse; Katharina Lindner; Antje Wick; Angelika Freitag; Lisa-Marie Lanz; Dominic Edelmann; Abigail Suwala; Michael O. Breckwoldt; Inga Harting; Felix Sahm; Richard F. Schlenk; Anita Schmitt; Oliver Schnell; Jörg Hense; Martin Misch; Dietmar Krex; Monika Denk; Juliane Walz; Joachim P. Steinbach; Andreas von Deimling; Michael Schmitt; Theresa Bunse; Ghazaleh Tabatabai; Martin Bendszus; Isabel Poschke; Wolfgang Wick; Michael Platten展开收起
作者单位
1. DKTK (German Cancer Consortium) Clinical Cooperation Unit (CCU) Neuroimmunology and Brain Tumor Immunology, German Cancer Research Center (DKFZ), Heidelberg, Germany; 2. Department of Neurology, Medical Faculty Mannheim, MCTN, University of Heidelberg, Mannheim, Germany; 3. German Cancer Consortium (DKTK), DKFZ, Core Center, Heidelberg, Germany; 4. Hertie Network of Excellence in Clinical Neuroscience, Tübingen, Germany; 5. DKFZ-Hector Cancer Institute at University Medical Center Mannheim, Mannheim, Germany; 6. Cluster of Excellence SynthImmune (EXC 3018/1) “Engineering Immune function with Synthetic Biology”, University of Heidelberg, Mannheim, Germany; 7. Immune Monitoring Unit, National Center for Tumor Diseases (NCT), Heidelberg, Germany; 8. Neurology Clinic and European Center for Neurooncology (EZN), Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany; 9. NCT Trial Management and Services, NCT, and German Cancer Research Center (DKFZ), Heidelberg, Germany; 10. Department of Neuropathology, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany; 11. Department of Neuroradiology, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany; 12. DKTK CCU Neuropathology, DKFZ, Heidelberg, Germany; 13. Department of Medical Oncology, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany; 14. Department of Internal Medicine V, Heidelberg University Hospital, University of Heidelberg, Heidelberg, Germany; 15. Neurosurgery Clinic, University Hospital Erlangen, Erlangen, Germany; 16. Department of Medical Oncology, West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany; 17. Department of Neurosurgery, Charité Medical Center, University of Berlin, Berlin, Germany; 18. Technische Universität Dresden, Faculty of Medicine and University Hospital Carl Gustav Carus, Department of Neurosurgery, Dresden, Germany; 19. Cluster of Excellence iFIT (EXC2180) ‘Image-Guided and Functionally Instructed Tumor Therapies’, University of Tübingen, Tübingen, Germany; 20. Department of Peptide-based Immunotherapy, Institute of Immunology, University and University Hospital Tübingen, Tübingen, Germany; 21. German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), partner site Tübingen, Tübingen, Germany; 22. Dr. Senckenberg Institute of Neurooncology, Frankfurt, Germany; 23. Department of Neurology and Neuro-Oncology, University Hospital Tübingen, Hertie Institute for Clinical Brain Research, Eberhard Karls University Tübingen, Tübingen, Germany; 24. Center for Neuro-Oncology, CCC Tübingen-Stuttgart in CCC-SW, Tübingen, Germany; 25. DKTK CCU Neurooncology, DKFZ, Heidelberg, Germany; 26. Helmholtz Institute for Translational Oncology (HI-TRON) Mainz, German Cancer Research Center, Mainz, Germany展开收起
313
天
Long-term outcomes of adjuvant metronomic capecitabine in locoregionally advanced nasopharyngeal carcinoma: a randomized, controlled, multicenter, phase 3 study
作者
Ya-Lan Tao; Dong-Hong Wu; Qin Zhou; Kun-Yu Yang; Feng Jin; Xiao-Dong Zhu; Mei Shi; Guo-Qing Hu; Yan Sun; Hong-Fen Wu; Hui Wu; Qin Lin; Hui Wang; Ye Tian; Ning Zhang; Xi-Cheng Wang; Liang-Fang Shen; Zheng-Zheng Liu; Jing Huang; Xiu-Ling Luo; Ling Li; Jian Zang; Qi Mei; Bao-Min Zheng; Dan Yue; Jing Xu; San-Gang Wu; Lei Chen; Wen-Fei Li; Guan-Qun Zhou; Rui Sun; Rui Guo; Yuan Zhang; Cheng Xu; Jia-Wei Lv; Ying Guo; Hui-Xia Feng; Ling-Long Tang; Fang-Yun Xie; Xu Liu; Ying Sun; Jun Ma; Yan-Ping Mao; Yu-Pei Chen展开收起
作者单位
1. Department of Radiation Oncology, State Key Laboratory of Oncology in South China, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Diagnosis and Therapy, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China; 2. Department of Oncology, Xiangya Hospital, Central South University, Changsha, China; 3. Department of Oncology, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; 4. Department of Oncology, Affiliated Hospital of Guizhou Medical University, Guiyang, China; 5. Department of Radiation Oncology, Affiliated Tumor Hospital of Guangxi Medical University, Department of Oncology, Affiliated Wuming Hospital of Guangxi Medical University, Nanning, China; 6. Department of Radiation Oncology, Xijing Hospital of Fourth Military Medical University, Xi’an, China; 7. Department of Oncology, Cancer Center, Tongji Hospital, Huazhong University of Science and Technology, Wuhan, China; 8. Department of Radiation Oncology, Peking University Cancer Hospital, Beijing, China; 9. Department of Radiation Oncology, Jilin Cancer Hospital, Changchun, China; 10. Department of Radiation Oncology, Henan Cancer Hospital, Zhengzhou, China; 11. Department of Radiation Oncology, Xiamen Cancer Center, The First Affiliated Hospital of Xiamen University, Xiamen, China; 12. Department of Radiation Oncology, Hunan Cancer Hospital and The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China; 13. Department of Radiation Oncology, The Second Affiliated Hospital of Soochow University, Suzhou, China; 14. Department of Radiation Oncology, The First People’s Hospital of Foshan, Foshan, China; 15. Department of Radiation Oncology, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China; 16. Clinical Trials Center, Sun Yat-sen University Cancer Center, Guangzhou, China展开收起
539
天
Inhibition of ADSS2-mediated de novo AMP biosynthesis re-sensitizes acute myeloid leukemia to BH3 mimetics
作者
Xin He; Lei Zhang; Yang Li; Song-Bai Liu; Zheng Li; Haojie Dong; Genevieve E. Baker; Le Xuan Truong Nguyen; Wei Chen; Jinhui Wang; Zhilian Jia; Xiyuan Lu; Yi-Chun Lin; Zunsong Hu; Umesh Prasad Yadav; Meng Liu; Lianjun Zhang; Zhenhua Chen; Xiwei Wu; Jianjun Chen; Chun-Wei Chen; Stefano Tiziani; Weidong Hu; Ya-Huei Kuo; Sheng-Li Xue; Yong Zhang; Min Li; Yaoqiu Zhu; Guido Marcucci; Zhaohui Gu; J. Jefferson P. Perry; Yun Lyna Luo; Ling Li展开收起
作者单位
1. Department of Hematological Malignancies Translational Science, Beckman Research Institute, City of Hope Medical Center, Duarte, USA; 2. Department of Hematology, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China; 3. Suzhou Key Laboratory of Medical Biotechnology, Suzhou Vocational Health College, Suzhou, China; 4. National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China; 5. Institute of Blood and Marrow Transplantation, Collaborative Innovation Center of Hematology, Soochow University, Suzhou, China; 6. Department of Molecular Diagnostics and Experimental Therapeutics, Beckman Research Institute, City of Hope Medical Center, Duarte, USA; 7. Integrative Genomics Core, Beckman Research Institute, City of Hope Medical Center, Duarte, USA; 8. Department of Computational and Quantitative Medicine & Systems Biology, City of Hope Medical Center, Duarte, USA; 9. Department of Nutritional Sciences, The University of Texas at Austin, Austin, USA; 10. College of Pharmacy, Western University of Health Sciences, Pomona, USA; 11. Department of Immunology and Theranostics, Beckman Research Institute, City of Hope Medical Center, Duarte, USA; 12. Department of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, USA; 13. Division of Biostatistics, Department of Computational and Quantitative Medicine, Beckman Research Institute, City of Hope Medical Center, Duarte, USA展开收起
668
天
GABA signaling activation drives glioblastoma progression in female mice through myeloid-derived suppressor cells
作者
Asmita Pathak; Palavalasa Sravya; Bruno Colon; Erika Ciervo; Yadi Zhou; Oriana Y. Teran Pumar; Brandon Emanuel León; Jonathan Mitchell; Pedro Henrique Assenza Tavares Coroa; Beatriz Mateo-Victoriano; Andrew J. Scott; Durga Prasad Gannamedi; Harrison K. A. Wong; Li Zhang; Juyeun Lee; Kristen Kay; Efe Karaca; Diana H. Chin; Haleh Amirian; Irem Karaman; Preyasha Shrestha; Katelyn Sellick; Danielle Dean; Daniel Bilbao Cortes; Jashodeep Datta; Scott M. Welford; Maria Clara Franco; Kiran Kurmi; Ashish H. Shah; Feixiong Cheng; Justin D. Lathia; Priyamvada Rai; David B. Lombard; Costas A. Lyssiotis; Dionysios C. Watson; Michele Ceccarelli; Daniel R. Wahl; Defne Bayik展开收起
作者单位
1. Department of Molecular and Cellular Pharmacology, Leonard M. Miller School of Medicine, University of Miami, Miami, USA; 2. Sylvester Comprehensive Cancer Center, University of Miami, Miami, USA; 3. Department of Radiation Oncology, University of Michigan, Ann Arbor, USA; 4. Rogel Cancer Center, University of Michigan, Ann Arbor, USA; 5. Genomic Medicine Institute, Cleveland Clinic Research, Cleveland Clinic, Cleveland, USA; 6. Leonard M. Miller School of Medicine, University of Miami, Miami, USA; 7. Medical Oncology, Leonard M. Miller School of Medicine, University of Miami, Miami, USA; 8. Department of Radiation Oncology, Leonard M. Miller School of Medicine, University of Miami, Miami, USA; 9. Department of Pathology and Laboratory Medicine, Leonard M. Miller School of Medicine, University of Miami, Miami, USA; 10. Department of Molecular and Integrative Physiology, University of Michigan, Ann Arbor, USA; 11. Department of Cancer Sciences, Cleveland Clinic Research, Cleveland, USA; 12. Department of Surgery, Leonard M. Miller School of Medicine, University of Miami, Miami, USA; 13. Vanderbilt University Medical Center, Nashville, USA; 14. Center for Translational Science, Florida International University, Port St. Lucie, USA; 15. Department of Cellular and Molecular Medicine, Florida International University, Miami, USA; 16. Department of Neurosurgery, Leonard M. Miller School of Medicine, University of Miami, Miami, USA; 17. Case Comprehensive Cancer Center, Cleveland, USA; 18. Rose Ella Burkhardt Brain Tumor & Neuro-Oncology Center, Cleveland Clinic, Cleveland, USA; 19. Miami VA Healthcare System, Miami, USA; 20. Department of Neurosurgery, University of Michigan, Ann Arbor, USA展开收起
Expert Matching · Case Demo
把投稿要求，转成可验证的期刊方案
说清专业、时限和作者背景，CrushSCI 结合真实审稿样本，给出拟题方向、期刊初筛与周期判断。
客户询问
我是环境工程专业，需要一篇 SCI，希望 3 个月内见刊。没有基金，也没有大牛挂名，可以投哪些期刊？
CrushSCI回复
可以。先按 90 天时限做可行性筛选，同步查找无基金、无知名作者挂靠的典型论文案例，作为选刊依据。重点核对研究质量与期刊 scope。
- 拟题建议
- 《融合机器学习与生命周期评价的城市污水处理碳排放预测与优化》
样本口径2026 年最近 5 篇有效论文样本
平均审稿62 天
中位数65 天